ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................*JBDM Ver 0.1.63 (23 May 2017) - 2999001/02970161CORRECTED EUROPEAN PATENT SPECIFICATIONB8B120181017W173deBibliographieenBibliographyfrBibliographieEP14717540.0201403072015100720161017enenen201361783213 P20130314US2018101720184220160120201603201808152018332018030120181017201842C07D 275/00 20060101AFI20141020BHEP C07D 333/32 20060101ALI20141020BHEP C07D 417/04 20060101ALI20141020BHEP C07D 417/12 20060101ALI20141020BHEP A61K 31/381 20060101ALI20141020BHEP A61K 31/425 20060101ALI20141020BHEP A61P 3/04 20060101ALI20141020BHEP A61P 3/10 20060101ALI20141020BHEP deGPR120-AGONISTEN ZUR BEHANDLUNG VON TYP-II-DIABETESenGPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETESfrAGONISTES DE GPR120 POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2WO-A2-2010/048207SUI, Zhihua2704 Baldeagle CircleNorristown, Pennsylvania 19403-1885USCAI, Chaozhong9 Banbury AvenueNorth Wales, Pennsylvania 19454USZHANG, XuqingWelsh&McKean RoadsSpring House, Pennsylvania 19477USJanssen Pharmaceutica NV101729817P067283EPTurnhoutseweg 302340 BeerseBECarpmaels & Ransford LLP101299776One Southampton RowLondon WC1B 5HAGBALATBEBGCHCYCZDEDKEEESFIFRGBGRHRHUIEISITLILTLULVMCMKMTNLNOPLPTRORSSESISKSMTRBA20151007ME20151007US201402173220140307enWO201415905420141002201440